SCHEDULE: ADAR1 Capital Management Discloses Yarrow Bioscience Stake

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 8.8% of Yarrow Bioscience, Inc. common stock as of June 30, 2026.

Summary

• ADAR1 Capital Management, LLC and Daniel Schneeberger have filed a joint Schedule 13G.
• This filing reports beneficial ownership of 59,000 shares of Yarrow Bioscience, Inc. common stock.
• This ownership represents 8.8% of the class of securities outstanding as of June 30, 2026.
• The shares are held directly by private investment funds managed by ADAR1 Capital Management, LLC.
• Daniel Schneeberger, as the sole manager of ADAR1 Capital Management, LLC, is deemed to indirectly beneficially own these securities.
• The filing is made in accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative disclosure of beneficial ownership rather than a strategic or financial update.

Positives

• Clear disclosure of beneficial ownership, providing transparency to the market.
• The reporting persons certify that their holdings are in the ordinary course of business, suggesting no intent to disrupt or control the company.

Negatives

• The filing does not contain any financial performance data or strategic updates, limiting its insight into the company's operational health.

Risks

• While not explicitly stated as a risk in this filing, significant ownership by investment entities can sometimes lead to activist investor actions or pressure on management, though this is not indicated here.
• The filing is based on data as of June 30, 2026, and market conditions or ownership may have changed since that date.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding future performance or strategy.

Management Comments

• ADAR1 Capital Management, LLC and Daniel Schneeberger certify that the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for significant beneficial ownership changes. This filing indicates a substantial, but not controlling, stake by an investment manager in a bioscience company, a sector often characterized by significant investment and development activities.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant beneficial owner, potentially influencing market perception.
• Management: May face increased scrutiny or engagement from ADAR1 Capital Management, LLC, although the filing indicates no intent to influence control.

Next Steps

• Continued monitoring of Yarrow Bioscience, Inc. for further ownership changes or strategic announcements.
• Review of future SEC filings by ADAR1 Capital Management, LLC and Daniel Schneeberger for any changes in beneficial ownership.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, ADAR1 Capital Management, Yarrow Bioscience, Investment Funds, Securities Exchange Act, Joint Filing Agreement